Skip to main content
. 2023 Mar 5;19(5):1645–1663. doi: 10.7150/ijbs.81939

Figure 3.

Figure 3

Establishment and validation of a BM-related signature to predict clinical outcome for breast cancer patients. (A) Principal component analysis (PCA) based on BMscore levels in TCGA-BRCA, METABRIC and GSE96058. (B and C) Distribution of patient survival status and survival time according to the BMscore in TCGA-BRCA, METABRIC and GSE96058. (D-G) Overall survival curves in TCGA-BRCA, METABRIC and GSE96058 (D), and KM-plotter curves of disease-free survival (E), disease-specific survival (F) and progression-free survival (G) in TCGA-BRCA.